By nuViteo Labs · Published · Editorial review
Scientific source verification through 2026-11-04. Publication and editorial-review dates describe preparation of these articles, not a new scientific reappraisal. The scientific source verification remains limited to the canonical release verified through 2026-11-04. This is a directed evidence selection, not a systematic review or GRADE assessment.
Editorial interpretation
maintenance is a different research question
An initial treatment response and the subsequent trajectory are related, but they are not the same endpoint. A trial measuring weight during treatment does not automatically show what happens after treatment stops. A withdrawal trial asks a more specific question: among the people who reach randomization after an initial treatment phase, what happens when treatment continues compared with a switch to placebo under the study's conditions?
The Weight maintenance journey makes that distinction explicit. The selected SURMOUNT-4 card concerns continuation versus withdrawal after an open-label lead-in. It is valuable evidence for that comparison, not a universal explanation of every person's long-term trajectory and not an evaluation of every possible maintenance strategy. The word long-term should never erase the actual follow-up interval or imply that outcomes beyond it were observed.
What the evidence shows
who entered the randomized withdrawal phase
The SURMOUNT-4 card describes adults without diabetes with obesity or overweight and a weight-related complication. The lead-in enrolled 783 people, of whom 782 received at least one dose. After 36 weeks, 670 participants who completed the lead-in and achieved a tolerated tirzepatide dose of 10 or 15 mg entered randomization. Each randomized arm included 335 participants, and lifestyle counseling continued in both groups.
These are not competing counts for the same population. They describe enrollment, exposure during lead-in, and the selected population entering the withdrawal comparison. The randomized findings should therefore be described as results after lead-in selection. They are not a description of everyone who might begin tirzepatide, including people who do not reach a tolerated dose or the point of randomization.
This design helps isolate the continuation-versus-switch comparison within the selected population, but it also narrows generalization. Selection is especially important when reading adverse-event information from the randomized phase. People already able to reach a tolerated dose are not interchangeable with an unselected group of new starters. Keeping that distinction visible is part of interpreting the trial, not an optional footnote.
What the evidence shows
change after randomization and the reference weight
From randomization at week 36 to week 88, the selected SURMOUNT-4 treatment-regimen results report a least-squares mean weight change of −5.5% with continued tirzepatide and +14.0% after switching to placebo. Their 95% confidence intervals were −6.8% to −4.2% and +12.8% to +15.2%, respectively. The published adjusted between-group difference was −19.4 percentage points, with a 95% confidence interval of −21.2 to −17.7 percentage points. These exact canonical results refer to the selected randomized full analysis population regardless of adherence.
All those percentages use body weight at week 36 as their reference, across the subsequent 52-week interval. The +14.0% result therefore does not mean that participants regained 14.0% of the weight they previously lost, and it is not a change measured from the original study baseline. The adjusted −19.4-percentage-point contrast is the published estimate; subtracting rounded arm means must not replace it. These distinctions are documented in the withdrawal evidence card.
The reported estimand concerns the average treatment effect for all randomized participants regardless of adherence. The canonical record describes ANCOVA and the published figure's hybrid imputation, while noting that detailed supplementary imputation was not reverified. The separate efficacy analysis uses different handling of post-discontinuation data. Its registry values must not be mixed with these primary treatment-regimen estimates, even if the trial name and outcome wording look similar.
Trace these results to their evidence cards
Exact result identifiers in the curated release:
Editorial interpretation
a group trajectory is evidence, not a verdict on a person
In this selected randomized comparison, continuation and switching to placebo produced different average weight trajectories. That is the finding. It does not show that every participant followed the group mean, that every future patient will experience the same change, or that a change in weight can be interpreted as a measure of personal effort. Keeping the analysis at its actual level avoids both blame and unrealistic reassurance.
Nor does the result prove that every individual must follow the same treatment course indefinitely. The card does not evaluate gradual tapering, alternative medications, or other maintenance strategies. It cannot choose between those options for a person. A discussion about continuing, changing, or stopping treatment needs individual clinical context, including reasons for the decision, relevant burdens, and what follow-up will be possible.
Planning for the trajectory is therefore different from trying to predict it exactly. A useful conversation can establish which outcomes matter, how concerns will be communicated, and which uncertainties remain. Those planning questions are practical applications of the study's limits, not interventions proven by the trial. This article provides a framework for asking them; it does not provide a withdrawal protocol.
Limits and uncertainty
safety selection, source access, and different follow-up questions
The selected SURMOUNT-4 safety findings describe the randomized phase and safety follow-up after lead-in selection. They should not be presented as new-starter risks or interpreted as evidence that continuation and withdrawal are equally safe. Descriptive event frequencies do not provide a complete individual benefit-risk assessment, and the absence of a verified confidence interval is not permission to reconstruct one or imply equivalence.
The STEP 1, SURMOUNT-1, and SURMOUNT-5 weight cards address treatment-period outcomes, not this randomized withdrawal comparison. The Tasali sleep-extension card provides a short intervention finding about estimated intake, not evidence of sustained weight-maintenance efficacy. These studies cannot be stitched into an observed longer trajectory that none actually measured.
The SURMOUNT-4 full text and official registry were consulted within the canonical scope, but not every supplementary analysis was reverified. The primary weight cards for the other named drug trials rely on the consulted original abstracts and registries; SURMOUNT-5 also includes its statistical analysis plan. The collection remains directed rather than exhaustive, without a GRADE assessment. Editorial preparation on the stated article date does not extend the scientific verification date or imply a fresh full-topic reappraisal.
Questions to take forward
make the transition an explicit topic
Ask: What question are we trying to answer now: initial treatment response, continued treatment, a possible transition, or management of a concern? How similar am I to the selected withdrawal-trial population? Which parts of the evidence are relevant to my situation, and which alternatives have not been evaluated by this card? What would we monitor if the plan changes?
Ask: Whom should I contact about adverse effects or concerns, and how will follow-up decisions be made? What do we know about weight, body composition, and function separately? Use Questions for Your Visit to prepare these topics. The GLP-1 treatments journey and SURMOUNT-5 Trial Inspector can support adjacent treatment-evidence questions, but neither should be mistaken for a maintenance calculator or a personal medication plan.